Novartis, slammed by Korean scandal, tweaks its ethics, compliance policies

FiercePharma, 15 May 2017
Author: Eric Sagonowsky
“Rocked by a corruption scandal in Korea and facing a kickbacks probe in Greece, Novartis says it’s strengthening and simplifying its global ethics and compliance approach. Last month, Korean authorities handed out a $50 million fine and suspended coverage on several Novartis meds in relation to a bribery probe in the country. Novartis employees conducted a kickbacks scheme through medical journal-sponsored meetings, with the total spent on bribes estimated to be $2.3 million, according to officials. Last year, Novartis agreed to a $25 million settlement with U.S. authorities to put to rest a bribery investigation in China.”
Find article here.